Targeting Urease: A Promising Adjuvant Strategy for Effective Helicobacter pylori Eradication.
Level 5 - mechanism / opinion, no new human data
Narrative review and mechanism-based reasoning without new human or clinical empirical data.
PubMed 40687008 · doi:10.1021/acsomega.5c02725
What was done
This narrative review synthesized structural characteristics of the Helicobacter pylori urease enzyme, its mechanistic role in bacterial survival within acidic gastric environments, known urease inhibitor classes and their pharmacophoric features, and computational docking scaffolds (including chlorogenic acid, catechol, and hydroxamic acid) for adjuvant drug design.
What was found
The abstract reports no numerical data. It describes the mechanistic pathway wherein bacterial urease converts urea into ammonia and carbon dioxide to neutralize local gastric acidity, enabling colonization, mucin attachment, and subsequent mucosal damage. The authors propose that co-administering urease inhibitors with standard antibiotic regimens could overcome common resistance and persistence mechanisms.
Why it matters
Helicobacter pylori eradication rates continue to fall due to rising antimicrobial resistance and biofilm formation. Mechanistic exploration of urease inhibition identifies molecular targets for potential adjuvant therapies to restore antibiotic susceptibility.
Limits
This is a narrative review without original clinical or experimental trial data. The abstract contains no quantitative metrics regarding inhibitor potency, pharmacokinetics, toxicity, or in vivo eradication efficacy.
Cited by
- supports Helicobacter pylori survives in the stomach by secreting alkaline ammonia to neutralize stomach acid.